Rosalind Advisors, Inc.

13D and 13G Filings

Issuer % of Class Filed
Schedule 13D · 2 securities · may seek to influence control
Neuraxis, INC 13D/A
NRXS · 64134X201
9.9% 11/16/2026
Event 9/30/2026
Delcath Systems, Inc. 13D/A
DCTH · 24661P807
9.9% 10/19/2026
Event 10/13/2026
Schedule 13G · 14 securities · passive
Talphera, Inc. 13G/A
TLPH · 00444T209
9.9% 11/13/2026
Event 9/30/2026
Biofrontera Inc. 13G/A
BFRI · 09077D209
9.9% 11/13/2026
Event 9/30/2026
PolyPid Ltd. 13G/A
PYPD · M8001Q126
9.6% 11/13/2026
Event 9/30/2026
MediWound Ltd. 13G/A
MDWD · M68830104
9.1% 11/13/2026
Event 11/5/2026
Myomo Inc. 13G/A
MYO · 62857J201
9.9% 11/12/2026
Event 9/30/2026
Femasys Inc 13G
FEMY · 31447E204
9.9% 8/14/2026
Event 8/10/2026
Regentis Biomaterials Ltd. 13G
001219096
9.9% 8/13/2026
Event 6/30/2026
Fennec Pharmaceuticals Inc. 13G/A
FENC · 31447P100
9.6% 8/13/2026
Event 6/30/2026
Kiora Pharmaceuticals, Inc. 13G/A
KPRX · 49721T101
9.9% 2/11/2026
Event 12/31/2025
InspireMD, Inc. 13G/A
NSPR · 45779A846
9.2% 2/11/2026
Event 12/31/2025
Cellectar Biosciences, Inc. 13G/A
CLRB · 15117F500
5.5% 2/10/2026
Event 12/31/2025
OptiNose, Inc. 13G/A
OPTN · 68404V209
0% 8/11/2025
Event 6/30/2025
Trevi Therapeutics, Inc. 13G/A
TRVI · 89532M101
1.2% 2/13/2025
Event 2/13/2025
Spruce Biosciences, Inc. 13G/A
SPRB · 85209E109
0% 2/13/2025
Event 12/31/2024

Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.